Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
about
Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against gram-negative bacteria collected from Shenyang, China.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Prospective monitoring of cefepime in intensive care unit adult patientsEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary diseaseIntraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studySystematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.Meropenem in the treatment of complicated skin and soft tissue infectionsEpidemiological interpretation of antibiotic resistance studies - what are we missing?Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.Pharmacodynamics of antimicrobials: treatment optimisation.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Cefepime: a reappraisal in an era of increasing antimicrobial resistance.Pharmacokinetic and pharmacodynamic properties of meropenem.Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisEvaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Impact of sample size on the performance of multiple-model pharmacokinetic simulations.Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe.Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
P2860
Q33603799-F5DBA144-2DFE-4644-B9FC-32BD471BAE0DQ33770046-6BEBA192-18E6-4093-B825-AAF726FFC384Q33919165-5780FD20-C9E2-4F0A-9EAB-C9FF8E7D9E16Q34077003-DB76625E-E54E-462C-875C-B6692E0D419FQ34188814-24101F4E-7980-4645-9099-E99407E4393EQ34297656-60A60E60-A37D-4DEF-B18C-70C330F87840Q35191511-99F5AC81-B751-45DB-9AEF-2A3635E075CAQ35739551-E3926462-91CD-4D92-9524-391A7F86DAB9Q35878860-A055C8F2-3F3F-4A28-8429-1EB616DABC32Q35919254-E6EAE5A1-5DEC-4C27-B916-1C6B61AA03EBQ35954276-DF223C43-E02A-47D3-877C-68F867623344Q36364174-309F5F33-DD28-4C18-B1E1-28611F4A3781Q36544935-2ED82395-F245-4FB1-A803-D387E67F8766Q36582692-EA4A6493-3983-494E-8A45-9F48F7F5134AQ37079350-10A81E53-A075-46BF-A8D5-F3D19298EDDEQ37247125-BC5CFBB9-756B-4E35-BC8B-80FCB4BB265EQ37335646-A69FF06D-8BA7-4B82-9301-A1A342371BE0Q38313276-9F55743F-BBE8-488C-9893-C29238E7416CQ39078075-4929358D-BBF2-4EC5-B1B7-BD26280761C2Q40982184-BB7954F3-4680-4C2D-81EC-3909C27A6718Q41727504-C41C1789-EFCB-4DED-91B6-3E254655084AQ45170003-B1056BFB-6F75-4E3F-B5AA-17A3B8F82673Q46133387-03751CE2-ADA1-47A4-AC2A-4EE476E168A6Q46573126-4438E686-193F-487A-B800-D5D195F95796Q46592051-E889639D-B9B4-4247-A618-8FF72A292F52Q54446298-C710FB6C-EF8E-464B-9743-4748E72EE722
P2860
Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@ast
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@en
type
label
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@ast
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@en
prefLabel
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@ast
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@en
P2093
P2860
P1476
Optimizing pharmacodynamic tar ...... cted in North America in 2002.
@en
P2093
Charles H Nightingale
David P Nicolau
Joseph L Kuti
P2860
P304
P356
10.1128/AAC.48.7.2464-2470.2004
P407
P577
2004-07-01T00:00:00Z